Pfizer’s world headquarters in New York City, US. Credit: Norbert Nagel, Mörfelden-Walldorf, Germany.

Pfizer has revealed plans to invest $465m for the construction of an advanced sterile injectable pharmaceutical manufacturing plant at Portage in Michigan, US.

The multi-storey, 400,000ft2 Modular Aseptic Processing (MAP) facility is intended to bolster the company’s production and supply capacity.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

MAP will feature advanced aseptic manufacturing equipment, systems and design. It will be equipped with multiple, self-contained modular manufacturing lines.

Pfizer chairman and CEO Ian Read said: “This investment is part of our overall plan announced in January to invest approximately $5bn in US-based capital projects as a result of the enactment of the Tax Cuts and Jobs Act.

“Every day, we strive to enhance our ability to bring medicines to the patients who need them, and the new facility we are building in Michigan will help us continue to deliver therapies that significantly improve people’s lives.”

Over the next several years, the new production facility is expected to create approximately 450 jobs in Portage where the company currently employs over 2,200 people at another site.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“This investment is part of our overall plan announced in January to invest approximately $5bn in US-based capital projects.”

Operational since 1948, the site primarily supplies more than 150 sterile injectable medicines, liquids and semi-solid therapeutics, as well as active pharmaceutical ingredients.

Pfizer Global Supply executive vice-president and president Kirsten Lund-Jurgensen said: “This investment will strengthen Pfizer’s leadership in sterile manufacturing technology and help meet growing patient demand.

“It also will create hundreds of highly skilled jobs, fortifying Michigan’s high-tech manufacturing environment.”

The company operates a total of 15 manufacturing and supply plants across the world. Its facilities in the US employ more than 11,000 staff.

Construction of the new US plant is set to begin next year and scheduled to be completed in 2021, with plans to commence production in 2024.